Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database

[1] Martins F(2019)Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 16 563-580

[2] Sofiya L(2019)Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis Nephrol Dial Transplant 34 108-117

[3] Sykiotis GP(2021)Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis Oncoimmunology 10 1927313-1700

[4] Manohar S(2021)Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study PLoS ONE 16 1692-131

[5] Kompotiatis P(2019)The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors Clin J Am Soc Nephrol 14 127-515

[6] Thongprayoon C(2021)Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity J Immunother 44 e002435-446

[7] Cheungpasitporn W(2021)Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events J Immunother Cancer. 9 504-1674

[8] Herrmann J(2020)Moving towards personalized treatments of immune-related adverse events Nat Rev Clin Oncol 17 435-1705

[9] Herrmann SM(2020)Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study J Am Soc Nephrol 31 e000467-487

[10] Abdelrahim M(2020)Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes J Immunother Cancer 8 1664-22

[1] Martins F(2019)Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance Nat Rev Clin Oncol 16 563-580

[2] Sofiya L(2019)Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis Nephrol Dial Transplant 34 108-117

[3] Sykiotis GP(2021)Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis Oncoimmunology 10 1927313-1700

[4] Manohar S(2021)Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study PLoS ONE 16 1692-131

[5] Kompotiatis P(2019)The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors Clin J Am Soc Nephrol 14 127-515

[6] Thongprayoon C(2021)Incidence and Prediction of Immune Checkpoint Inhibitor-related Nephrotoxicity J Immunother 44 e002435-446

[7] Cheungpasitporn W(2021)Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events J Immunother Cancer. 9 504-1674

[8] Herrmann J(2020)Moving towards personalized treatments of immune-related adverse events Nat Rev Clin Oncol 17 435-1705

[9] Herrmann SM(2020)Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study J Am Soc Nephrol 31 e000467-487

[10] Abdelrahim M(2020)Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes J Immunother Cancer 8 1664-22